11.11
price down icon1.10%   -0.1211
 
loading
전일 마감가:
$11.23
열려 있는:
$11.14
하루 거래량:
49,718
Relative Volume:
0.08
시가총액:
$768.33M
수익:
-
순이익/손실:
$-209.96M
주가수익비율:
-3.7404
EPS:
-2.97
순현금흐름:
$-176.27M
1주 성능:
-2.57%
1개월 성능:
-2.14%
6개월 성능:
+99.40%
1년 성능:
+6.49%
1일 변동 폭
Value
$11.06
$11.35
1주일 범위
Value
$10.57
$11.50
52주 변동 폭
Value
$4.92
$12.97

레플리뮨 Stock (REPL) Company Profile

Name
명칭
Replimune Group Inc
Name
전화
(781) 222-9600
Name
주소
500 UNICORN PARK, WOBURN, MA
Name
직원
331
Name
트위터
@Replimune
Name
다음 수익 날짜
2024-11-05
Name
최신 SEC 제출 서류
Name
REPL's Discussions on Twitter

REPL을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
REPL 11.14 768.33M 0 -209.96M -176.27M -2.97
VRTX 447.58 115.74B 10.63B -479.80M -1.35B 13.33
REGN 741.92 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 589.39 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.84 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 103.41 24.49B 3.30B -501.07M 1.03B 11.54

레플리뮨 Stock (REPL) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2023-04-17 재개 Piper Sandler Overweight
2021-11-19 개시 Piper Sandler Overweight
2021-10-15 재개 BTIG Research Buy
2020-11-17 개시 BTIG Research Buy
2020-11-02 개시 Jefferies Buy
2020-10-15 업그레이드 H.C. Wainwright Neutral → Buy
2020-07-01 다운그레이드 H.C. Wainwright Buy → Neutral
2020-05-05 개시 Barclays Overweight
2019-09-04 개시 ROTH Capital Buy
2019-07-23 개시 Chardan Capital Markets Buy
2019-07-12 업그레이드 JP Morgan Neutral → Overweight
2019-07-08 개시 H.C. Wainwright Buy
2019-04-25 개시 Wedbush Outperform
2019-01-23 다운그레이드 JP Morgan Overweight → Neutral
2018-08-14 개시 JP Morgan Overweight
2018-08-14 개시 Leerink Partners Outperform
모두보기

레플리뮨 주식(REPL)의 최신 뉴스

pulisher
12:53 PM

Replimune's chief commercial officer sells $56,131 in stock By Investing.com - Investing.com Nigeria

12:53 PM
pulisher
Nov 20, 2024

Replimune group's chief medical officer sells shares worth $78,111 By Investing.com - Investing.com Canada

Nov 20, 2024
pulisher
Nov 20, 2024

Replimune's chief commercial officer sells $56,131 in stock - Investing.com

Nov 20, 2024
pulisher
Nov 20, 2024

REPL (Replimune Group) Peter Lynch Fair Value : N/A (As of Nov. 20, 2024) - GuruFocus.com

Nov 20, 2024
pulisher
Nov 20, 2024

Replimune Group, Inc. (NASDAQ:REPL) Shares Acquired by LMR Partners LLP - MarketBeat

Nov 20, 2024
pulisher
Nov 17, 2024

Replimune Group Q3 EPS Forecast Decreased by Leerink Partnrs - Defense World

Nov 17, 2024
pulisher
Nov 15, 2024

What is Wedbush's Estimate for Replimune Group Q3 Earnings? - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

HC Wainwright Predicts Stronger Earnings for Replimune Group - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

Leerink Partnrs Weighs in on Replimune Group Q3 Earnings - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

Significant Stake Increase by Baker Bros. Advisors in Replimune Group Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

Brokerages Set Replimune Group, Inc. (NASDAQ:REPL) Target Price at $16.80 - Defense World

Nov 15, 2024
pulisher
Nov 14, 2024

When (REPL) Moves Investors should Listen - Stock Traders Daily

Nov 14, 2024
pulisher
Nov 13, 2024

Replimune Group’s Q3 2024 Financial Highlights - TipRanks

Nov 13, 2024
pulisher
Nov 13, 2024

Replimune Group Inc. (REPL) Quarterly 10-Q Report - Quartzy

Nov 13, 2024
pulisher
Nov 12, 2024

Replimune Group (NASDAQ:REPL) Receives Buy Rating from HC Wainwright - MarketBeat

Nov 12, 2024
pulisher
Nov 12, 2024

Replimune Reports $432.1M Cash Position, Advances Melanoma Treatment BLA Plans | REPL Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 12, 2024

Replimune stock soars to 52-week high, touches $12.86 By Investing.com - Investing.com Australia

Nov 12, 2024
pulisher
Nov 12, 2024

Analysts Set Replimune Group, Inc. (NASDAQ:REPL) Price Target at $16.80 - MarketBeat

Nov 12, 2024
pulisher
Nov 11, 2024

Replimune stock soars to 52-week high, touches $12.86 - Investing.com India

Nov 11, 2024
pulisher
Nov 11, 2024

Replimune Group (NASDAQ:REPL) Hits New 52-Week HighStill a Buy? - MarketBeat

Nov 11, 2024
pulisher
Nov 11, 2024

Creative Planning Buys 4,699 Shares of Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Nov 11, 2024
pulisher
Nov 09, 2024

Replimune's RP1 Shows 33.6% Response Rate in Melanoma Trial, Marks Breakthrough | REPL Stock News - StockTitan

Nov 09, 2024
pulisher
Nov 08, 2024

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Nov 08, 2024
pulisher
Nov 08, 2024

Replimune Group Awards Stock Options, RSUs to New Employees in Retention Move | REPL Stock News - StockTitan

Nov 08, 2024
pulisher
Nov 06, 2024

TSX Consumer Staples Capped Index (TTCS) QuotePress Release - The Globe and Mail

Nov 06, 2024
pulisher
Nov 06, 2024

KBW Bank Index (BKX) QuotePress Release - The Globe and Mail

Nov 06, 2024
pulisher
Nov 05, 2024

Itron Inc (ITRI-Q) QuotePress Release - The Globe and Mail

Nov 05, 2024
pulisher
Nov 05, 2024

Vanguard Group's Strategic Acquisition in Replimune Group Inc - GuruFocus.com

Nov 05, 2024
pulisher
Nov 05, 2024

Teledyne Technologies Inc (TDY-N) QuotePress Release - The Globe and Mail

Nov 05, 2024
pulisher
Oct 30, 2024

Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - The Manila Times

Oct 30, 2024
pulisher
Oct 28, 2024

Masco Corp (MAS-N) QuotePress Release - The Globe and Mail

Oct 28, 2024
pulisher
Oct 25, 2024

Skechers U.S.A. (SKX-N) QuotePress Release - The Globe and Mail

Oct 25, 2024
pulisher
Oct 24, 2024

S&P GSCI Index (GNX) QuotePress Release - The Globe and Mail

Oct 24, 2024
pulisher
Oct 23, 2024

Non-melanoma Skin Cancer is Predicted to Exhibit Remarkable Growth During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.

Oct 23, 2024
pulisher
Oct 22, 2024

SG Americas Securities LLC Invests $251,000 in Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Oct 22, 2024
pulisher
Oct 18, 2024

Replimune Group, Inc. (NASDAQ:REPL) Given Average Recommendation of "Buy" by Analysts - MarketBeat

Oct 18, 2024
pulisher
Oct 16, 2024

It would be worthwhile to take a closer look at Replimune Group Inc (REPL) - US Post News

Oct 16, 2024
pulisher
Oct 15, 2024

Daily Progress: Replimune Group Inc (REPL) Drop -7.06, Closing at 10.67 - The Dwinnex

Oct 15, 2024
pulisher
Oct 15, 2024

Replimune Group Inc [REPL] Insider Selling: Time to sell? - Knox Daily

Oct 15, 2024
pulisher
Oct 15, 2024

Replimune Group Inc Inc. (REPL) Price Performance: A Comparative Analysis with Competitors - The InvestChronicle

Oct 15, 2024
pulisher
Oct 14, 2024

Replimune Group (NASDAQ:REPL) Stock Price Down 5.2%Here's What Happened - MarketBeat

Oct 14, 2024
pulisher
Oct 13, 2024

Learn to Evaluate (REPL) using the Charts - Stock Traders Daily

Oct 13, 2024
pulisher
Oct 13, 2024

Cubist Systematic Strategies LLC Buys 53,313 Shares of Replimune Group, Inc. (NASDAQ:REPL) - MarketBeat

Oct 13, 2024
pulisher
Oct 09, 2024

Gaining Ground: Replimune Group Inc (REPL) Closes Higher at 11.74, Up 3.62 - The Dwinnex

Oct 09, 2024
pulisher
Oct 09, 2024

Investing in Replimune Group Inc (REPL) Is Getting More Attractive - Knox Daily

Oct 09, 2024
pulisher
Oct 09, 2024

Replimune Group, Inc. (NASDAQ:REPL) Shares Sold by Dimensional Fund Advisors LP - MarketBeat

Oct 09, 2024
pulisher
Oct 07, 2024

Morgan Stanley's Strategic Reduction in Replimune Group Inc Holdings - GuruFocus.com

Oct 07, 2024
pulisher
Oct 04, 2024

Cubist Systematic Strategies LLC Increases Position in Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Oct 04, 2024
pulisher
Oct 04, 2024

Replimune Group, Inc. (NASDAQ:REPL) Shares Purchased by Millennium Management LLC - MarketBeat

Oct 04, 2024
pulisher
Oct 03, 2024

Chief Financial Officer Hill Emily Luisa sale 8,938 shares of Replimune Group Inc [REPL] - Knox Daily

Oct 03, 2024
pulisher
Oct 02, 2024

Insiders At Replimune Group Sold US$863k In Stock, Alluding To Potential Weakness - Simply Wall St

Oct 02, 2024

레플리뮨 (REPL) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

레플리뮨 주식 (REPL) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Sarchi Christopher
Chief Commercial Officer
Nov 18 '24
Sale
10.78
5,207
56,131
87,045
Hill Emily Luisa
Chief Financial Officer
Aug 16 '24
Sale
10.18
8,938
90,989
101,057
Xynos Konstantinos
Chief Medical Officer
Jun 07 '24
Sale
7.50
15,881
119,108
117,131
Sarchi Christopher
Chief Commercial Officer
May 16 '24
Sale
6.47
2,218
14,350
92,252
Schwendenman Andrew
Chief Accounting Officer
May 16 '24
Sale
6.47
2,298
14,868
38,238
Love Colin
Chief Operating Officer
May 16 '24
Sale
6.47
17,615
113,969
777,345
Astley-Sparke Philip
Executive Chairman
May 16 '24
Sale
6.47
37,928
245,394
1,487,350
Coffin Robert
Director
May 16 '24
Sale
6.47
11,464
74,172
1,821,872
Patel Sushil
Chief Executive Officer
May 16 '24
Sale
6.47
20,194
130,655
212,014
Xynos Konstantinos
Chief Medical Officer
May 16 '24
Sale
6.47
6,367
41,194
133,012
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
자본화:     |  볼륨(24시간):